Hypothalamic GLP-1 Response in Healthy Weight and Obesity

Korábbi kezelés

• Treatment with GLP-1 receptor agonists or other GLP-1-based therapies within the past three months
• Previous bariatric surgery
• Women using hormonal contraception (oral contraceptives, progestin- containing implants or hormonal intrauterine device.)

Más betegség

• Current eating disorder (anorexia nervosa, bulimia nervosa)
• Contraindications to study procedures, including:
  • Esophageal or nasal obstruction (e.g. tumors, strictures)
  • Coagulopathy
  • History of skull base trauma
  • Esophageal varices
  • Hiatal hernia
  • Claustrophobia
  • Inability to comply with MRI requirements (e.g. remaining still)
  • Presence of non-removable magnetic objects incompatible with MRI
  • Any other condition or circumstance that, in the opinion of the study physician, may compromise safe participation in the study.

Laborértékek

• Diabetes mellitus type 1 or type 2, or fasting plasma glucose > 7.0 mmol/L
• Use of medication affecting appetite, body weight, or glucose metabolism within the past three months
• Known serious chronic disease, including but not limited to:
  • Heart disease
  • Anemia (hemoglobin <7.0 mmol/L for women, <8.0 mmol/L for men)
  • Renal impairment (eGFR <60 mL/min/1.73m²)
  • Hepatic impairment (ALT or AST >3 times upper limit of normal)

Egyéb

• Known monogenic obesity
• Substance abuse (current or within the past year)
• Pregnancy, breastfeeding, or wish to become pregnant during the study period
• Women of childbearing potential not using adequate contraception

• Group 1:
• Age 18-75 years
• BMI 18.5-25 kg/m²
• Normal glucose tolerance (Fasting glucose < 5.6 mmol/L)
  • Group 2:
• Age and sex-matched with group 1
• BMI≥30 kg/m²
• Impaired glucose tolerance (Fasting glucose 5.6 - 6.9 mmol/L)